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Background: SRD5A3 is responsible for SRD5A3-CDG, a type of congenital disorder of glycosylation, and mutations
have been reported in 15 children. All the mutations are recessive and truncating.
Case presentation: We present 2 brothers at the age of 38 and 40 years with an initial diagnosis of cerebellar
ataxia. We found the candidate disease loci via linkage analysis using data from single nucleotide polymorphism
genome scans and homozygous truncating mutation SRD5A3 p.W19X, which was previously reported in 3
unrelated children, by exome sequencing.
Clinical investigations included physical and ocular examinations and blood tests. Severe ocular involvement with
retinal bone spicule pigmentation and optic atrophy are the most prominent disabling clinical features of the
disease. The serum transferrin isoelectric focusing (TIEF) pattern is abnormal in the patient investigated.
Conclusion: Our patients are older, with later onset and milder clinical phenotypes than all patients with
SRD5A3-CDG reported so far. They also have atypical ocular findings and variable phenotypes. Our findings widen
the spectrum of phenotypes resulting from SRD5A3 mutations and the clinical variability of SRD5A3-CDG, and suggest
screening for SRD5A3 mutations in new patients with at least a few of the clinical symptoms of SRD5A3-CDG.
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Congenital disorders of glycosylation (CDG) are multisys-
temic disorders caused by defects in protein glycosylation.
Since the first clinical description in 1980, about 60 CDG
types with a very broad spectrum of clinical presentations
have been reported [1,2]. SRD5A3, encoding steroid 5-
alpha-reductase 3, is responsible for a rare CDG, namely,
SRD5A3-CDG [CDG1Q; MIM 612379] [3,4]. So far, 15
children with SRD5A3-CDG in 12 families carrying 10 dif-
ferent recessive mutations and with variable phenotypes
have been reported [3-7]. The disorder is characterized by
severe early visual impairment and variable ocular anom-
alies including coloboma, optic nerve hypoplasia, congeni-
tal cataract, and glaucoma, as well as some degree of
intellectual disability. Other clinical features, such as cere-
bellar ataxia and cerebellar malformations, ichthyosiform* Correspondence: tolun@boun.edu.tr
†Equal contributors
2Department of Molecular Biology and Genetics, Boğaziçi University, Istanbul,
Turkey
Full list of author information is available at the end of the article
© 2014 Kara et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orskin disorders, hypertrichosis, congenital heart defects,
and abnormal coagulation vary considerably not only
among families but also within a family [5]. Although the
transferrin isoelectric focusing (TIEF) pattern is generally
abnormal in affected individuals, one patient with
SRD5A3-CDG was reported to have a normal pattern [5].
Therefore, even in the absence of an abnormal TIEF pat-
tern, the clinically distinctive features of SRD5A3-CDG
warrant genetic testing. Kahrizi syndrome is a similar dis-
ease and has been described in a single family. It has been
characterized by intellectual disability, coloboma, cataract,
and kyphosis but a normal TIEF pattern [8]. It was later
shown to result from a homozygous truncating SRD5A3
mutation, indicating that SRD5A3-CDG and Kahrizi syn-
drome are allelic disorders [9]. The affected siblings were
aged 40 years and older. In contrast, all patients with
SRD5A3-CDG reported so far have been children.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Family
The parents were second cousins. They had 2 affected
sons and 4 healthy daughters. Peripheral blood samples
were obtained after written informed consent, and DNA
was isolated from leukocytes by a standard protocol.
Genetic analyses
Single nucleotide polymorphism (SNP) genome scans were
performed for the parents and the 2 affected sibs using an
Illumina 370 Duo chip. Linkage analysis for calculating
multipoint logarithm of the odds (LOD) scores was per-
formed with Allegro using SNPs at intervals of 0.07 cM
and sets of 100, and assuming recessive inheritance and a
disease allele frequency of 0.001. Four candidate loci
yielded the highest score of 2.66 (Additional file 1). The
largest locus was maximally 52 Mbp at chromosome 4q12-
24. The others were 0.55 to 5.5 Mbp at 6q25.1-25.2 (max-
imally between rs912561 and rs1407490), 12p13.31-p13.1
(rs1868798 and rs873218), and 22q12.1 (rs1547358 and
rs5752043). We considered the largest locus (4q12-24) the
most likely disease locus. The region with shared homozy-
gosity was delineated by rs2067951 and rs11733406
(55,805,555 and 107,751,089 bp) and harbored 437 genes
[10]. At the time, there were no similar diseases mapped to
any of the loci. The abundance of the genes at the loci dis-
couraged us from applying the candidate gene approach,
and we launched exome sequencing.
A DNA sample from the older brother was subjected to
exome sequencing analysis, aiming to cover 95% of the
CCDS database, as previously described [11]. Ten novel
exonic variants were found at 4q12-24. The best candidate
responsible for the disease was the homozygous mutation
c.57G > A (p.W19X) in SRD5A3 exon 1, converting codon
19 (tryptophan) to a termination codon. We validated the
mutation by Sanger sequencing (Additional file 2). The
mutation segregated with the disease in the family. Fifty-
six unrelated individuals from the population were
screened for the mutation by single strand conformational
polymorphism analysis and found not to carry it. The mu-
tation was reported in 3 unrelated children with SRD5A3-
CDG [4,6].
Clinical data
The affected brothers were 38 and 40 years old and had
complaints of abnormal gait and visual impairment, and
the initial diagnosis five years ago was diagnosed with
cerebellar ataxia. According to the parents, their prenatal,
natal, and postnatal histories were uneventful. They
walked and spoke single words by the age of 2 years.
Whether they had childhood ichthyosiform dermatitis or
coagulation abnormalities could not be assessed with cer-
tainty. Progressive ataxic gait and visual impairment began
in early childhood. The older brother had a relatively moresevere phenotype and could not complete primary school
due to intellectual disability and ophthalmologic problems.
At present, he lives with his parents, needs help with activ-
ities of daily living partly due to ophthalmologic problems,
and does not have a job. The younger brother was able to
complete primary school but not high school mainly due
to ophthalmologic problems. At present, he works in an
office and can use a computer. He is married and has 4
healthy children. Recent examinations of both patients re-
vealed ataxic gait, dysmetria, dysdiadochokinesia, and
scanning speech. Muscle tonus was normal, deep tendon
reflexes were increased, and Achilles clonus was present.
No pathologic reflex was observed. Cranial nerves were
intact. The mental performance of the younger patient
seemed much better. His sensory examination was normal
and visual acuity was at the level of counting fingers from
25 cm. The older brother’s visual acuity was at the level of
awareness of hand movements right in front of his face. In
both patients, eye examination showed bilateral horizontal
nystagmus, bilateral posterior subcapsular cataract,
bilateral optic disk hypoplasia, thinning of the retinal
arterioles, bilateral optic atrophy, and retinal bone spicule
pigmentation (Figure 1). The younger patient also had
30–40° exotropia, bilateral keratoconus, and degenerated
vitreous. Neither of the patients had glaucoma, dysmorph-
ism, or organomegaly. Skin examinations were normal.
The upper extremities of the older brother were slightly
short. Whole blood count, coagulation studies, urine
analysis, and serum biochemistry were performed for him,
and the results were unremarkable.
Serum transferrin isoelectric focusing
In order to verify that the disease was SRD5A3-CDG,
we performed serum TIEF (in the older brother) and
found an abnormal pattern compatible with SRD5A3-
CDG: 5.371% disialotransferrin, 3.546% trisialotransferrin,
86.012% tetrasialotransferrin, and 5.071% pentasialotrans-
ferrin. The presence of disialotransferrin and a decreased
ratio of trisialotransferrin to diasialotransferrin of 0.66
(normal ratio >1.25) was supportive of a type I pattern.
Considering all evidence together, the patients were di-
agnosed with SRD5A3-CDG.
Discussion
The 2 brothers were initially evaluated as having a novel
neurologic disorder. We performed genome-wide linkage
analysis and found 4 candidate loci. We then launched ex-
ome sequencing and found a homozygous nonsense muta-
tion in SRD5A3 exon 1. The premature translational
termination signal was deduced to result in a null protein
by deleting 300 residues from the native 318-amino acid
protein. The gene has recently been shown to be respon-
sible for SRD5A3-CDG, and all mutations reported so far
are truncating [3,4,7,9]. Each of the mutations was found
Figure 1 Ocular findings. A: Waxy pallor of the optic disc with
attenuated retinal vessels and bone spicule-shaped pigment deposits
in the periphery (indicated with arrows) in the older patient. B: Blurry
fundus due to vitreous degeneration and a posterior subcapsular
cataract in the younger brother.
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patients. This mutation was previously reported in the
homozygous state in 3 unrelated children [4,6]. The vari-
ability and severity of the clinical phenotypes of those pa-
tients plus the two patients we present herein with the
same homozygous mutation further establish that there is
no genotype–phenotype correlation in SRD5A3-CDG and
clinical manifestations may vary even within the same
family. Both of the previously reported Turkish patients
with p.W19X were initially diagnosed with CDG-x [12,13]
but later shown to have SRD5A3mutation [4]. One of those
patients presented with stereotypical dystonic hand move-
ments, truncal hypotonia, cerebellar vermis atrophy, psy-
chomotor retardation, and ophthalmologic abnormalities
such as optic atrophy, nystagmus and strabismus [13]. Theother patient had floppiness, roving eye movements, and
normal social contact in early infancy. Muscle hypotonia
developed at the age of 5 months, and severe mental delay,
visual impairment, optic atrophy, nystagmus, cerebellar
ataxia, and recurrent episodes of reduced activity followed
[12]. The third patient reported with p.W19X was a 6-year
old Pakistani boy with clinical features of hypertonia, psy-
chomotor retardation, and nystagmus but no ocular find-
ings at the age 5 months [6]. In contrast, our patients had
progressive ataxic gait and visual failure since early child-
hood, and the older brother had a more severe phenotype.
Our findings widen the clinical spectrum of SRD5A3
mutations, especially at the adult stage. Our patients are
around 40 years of age, whereas all previously reported
cases of SRD5A3-CDG were children. The most striking
clinical features in our patients are ophthalmologic malfor-
mations including bilateral optic atrophy, cataracts and vis-
ual failure, ataxia and mental status best described as
borderline in the younger brother and moderate intellec-
tual disability in the older brother. The phenotype of the
younger patient is quite mild and very slowly progressive.
The clinical features of our patients and those of the re-
ported patients with SRD5A3 mutation are compared in
Table 1. The leading clinical pathology in SRD5A3-CDG
seems to include ophthalmic malformations involving both
the anterior and posterior segments of the eye, such as
ocular coloboma, hypoplasia of the optic nerve, cataract,
glaucoma, and variable visual impairment with nystagmus.
Both of our patients have severe visual impairment, optic
atrophy, and cataracts. Cataracts were reported in only 2
patients with SRD5A3-CDG but in all 3 patients with
Kahrizi syndrome [3,4,9]. It was suggested that cataracts
could develop later in patients with SRD5A3-CDG, if not
already present at infancy [4]. Congenital colobomas, al-
though extremely rare in CDG syndromes, are suggestive
of SRD5A3-CDG whenever present, and glaucoma is de-
scribed in SRD5A3-CDG but not other types of CDG
[4,5,14]. Neither of these 2 pathologies was observed in our
patients. However, bone spicule pigmentation, which is a
fundus feature in retinitis pigmentosa, another rare ocular
pathology, was present in both of our patients. Although
retinitis pigmentosa has been reported in SRD5A3-CDG
[5,14], our patients had a specific form resulting from the
migration of pigment-containing cells to perivascular sites
in the inner retina. Retinitis pigmentosa might be a late
sign in SRD5A3-CDG, and so is optic disc hypoplasia. Only
3 of the 12 patients in the Morava cohort [4] had this fea-
ture, whereas both our patients had it. It remains to be
seen whether bone spicule pigmentation, observed so far
only in our patients, is a frequent late manifestation of
SRD5A3-CDG. It was not reported in the 3 siblings with
Kahrizi syndrome either; they had cataracts and iris colo-
boma but not optic atrophy, optic disc hypoplasia, or retin-
itis pigmentosa.
Table 1 Characteristics of patients with SRD5A3 mutation
Clinical findings Morava cohort [4] Kahrizi cohort [8] Kasapkara patient [7] Our patients [this paper]
Origin
Turkish 5/12 0/3 1/1 2/2
Iranian 0/12 3/3 0/1 0/2
Baluchi 4/12 0/3 0/1 0/2
Polish 3/12 0/3 0/1 0/2
Age at diagnosis 6 month-12 years Adulthood 3.5 years Adulthood
Eye findings
Ocular coloboma 5/12 2/3 0/1 0/2
Hypoplasia of optic discs 3/12 0/3 1/1 0/2
Optic atrophy 8/12 0/3 1/1 2/2
Nystagmus 12/12 0/3 1/1 2/2
Glaucoma 1/12 0/3 0/1 0/2
Cataract 2/12 3/3 0/1 0/2
Bone spicule pigmentation 0/12 0/3 0/1 2/2
Visual impairment 11/12 ?/3 1/1 2/2
Strabismus NA 0/3 1/1 0/2
Microphthalmia 2/12 0/3 0/1 0/2
Neurologic findings
Muscle hypotonia 10/12 0/3 1/1 0/2
Motor retardation 8/12 3/3 1/1 2/2
Intellectual disability 12/12 3/3 1/1 2/2
Cerebellar vermis atrophy 5/11 0/3 1/1 NA
Global cerebellar atrophy 2/11 0/3 1/1 NA
Cerebellar ataxia 10/11 0/3 1/1 2/2
Spasticity 5/12 0/3 0/1 2/2
Movement disorder 3/12 0/3 0/1 0/2
Stereotypic movements 3/12 0/3 0/1 0/2
Seizures NA 0/3 0/1 0/2
Microcephaly NA 0/3 1/1 0/2
Dysmorphism ?/12 3/3 1/1 0/2
Ichthyosiform skin lesions 1/12 0/3 1/1 0/2
Hepato-intestinal disease 0/12 0/3 0/1 0/2
Skeletal findings
Kyphosis 0/12 3/3 0/1 0/2
Short upper extremities 0/12 0/3 0/1 1/2
Contractures of large joints 0/12 3/3 0/1 0/2
Congenital cardiac abnormalities 3/12 0/3 1/1 NA
Coagulation abnormalities 7/8 NA 0/1 0/1
Elevated liver enzymes 9/10 NA 0/1 0/1
Microcytic anemia 8/11 NA 0/1 0/1
Type I TIEF pattern 12/12 0/3 1/1 1 + NA/2
W19X mutation 2/12 0/2 0/1 2/2
? = the number of patients having the phenotype was not specified; NA = phenotype not assessed.
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We suggest screening for SRD5A3 mutations in new
patients with at least a few of the clinical symptoms of
SRD5A3-CDG such as ophthalmologic malformations,
visual impairment, cerebellar abnormalities, ichthyosiform
skin lesions, abnormal coagulation, and psychomotor re-
tardation, bearing in mind that a normal TIEF pattern
does not exclude the diagnosis. The disorder is a clinically
recognizable cerebello-ophthalmo-cutaneous syndrome;
therefore, even in the absence of abnormal TIEF results,
the above-mentioned distinctive features warrant genetic
testing for SRD5A3 [15]. Only one family has been reported
with Kahrizi syndrome, an allelic disease; the 3 affected sib-
lings were 40 years or older and had normal TIEF patterns.
It was suggested that the TIEF pattern might become nor-
mal in adults and the normal pattern in those patients
could be due to their older age [16]. The abnormal TIEF
pattern in our patient does not support this hypothesis.
Our findings widen the spectrum of the clinical mani-
festations of SRD5A3-CDG. We emphasize that ocular
signs seem to increase with age and patient follow-up
with this knowledge in mind could benefit patients diag-
nosed at a young age.
Consent
Informed consent was obtained for all 4 participants. The
father signed the consent forms for the sons. Written in-
formed consent had been obtained also from the fifty-six
unrelated individuals who were screened for the mutation;
the samples are part of the anonymized group used for mu-
tation screening in our laboratory. The Boğaziçi University
Institutional Review Board for Research with Human
Participants approved the study protocol. A copy of the
written consent is available for review by the Series Editor
of this journal.
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was amplified using primers with sequences 5′-GGAGGCCGAGCACTCG
and 5′-GCAGCCCGGGAGCAG.
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